JP2009538286A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538286A5
JP2009538286A5 JP2009511526A JP2009511526A JP2009538286A5 JP 2009538286 A5 JP2009538286 A5 JP 2009538286A5 JP 2009511526 A JP2009511526 A JP 2009511526A JP 2009511526 A JP2009511526 A JP 2009511526A JP 2009538286 A5 JP2009538286 A5 JP 2009538286A5
Authority
JP
Japan
Prior art keywords
mage
composition according
antigen
composition
vaccinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538286A (ja
Filing date
Publication date
Priority claimed from GB0610547A external-priority patent/GB0610547D0/en
Priority claimed from GB0707307A external-priority patent/GB0707307D0/en
Application filed filed Critical
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Publication of JP2009538286A publication Critical patent/JP2009538286A/ja
Publication of JP2009538286A5 publication Critical patent/JP2009538286A5/ja
Pending legal-status Critical Current

Links

JP2009511526A 2006-05-26 2007-05-24 癌に対するワクチン接種 Pending JP2009538286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610547A GB0610547D0 (en) 2006-05-26 2006-05-26 Method
GB0707307A GB0707307D0 (en) 2007-04-16 2007-04-16 Method
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer

Publications (2)

Publication Number Publication Date
JP2009538286A JP2009538286A (ja) 2009-11-05
JP2009538286A5 true JP2009538286A5 (https=) 2010-07-08

Family

ID=38349515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511526A Pending JP2009538286A (ja) 2006-05-26 2007-05-24 癌に対するワクチン接種

Country Status (5)

Country Link
US (1) US20090186049A1 (https=)
EP (1) EP2021017A2 (https=)
JP (1) JP2009538286A (https=)
CA (1) CA2653402A1 (https=)
WO (1) WO2007137986A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
ES2398492T3 (es) * 2007-01-15 2013-03-19 Glaxosmithkline Biologicals Sa Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
RU2014122867A (ru) * 2011-12-22 2016-02-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
CN105181966B (zh) * 2015-09-02 2017-08-11 南通大学附属医院 一种mage‑a9的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine

Similar Documents

Publication Publication Date Title
JP2009538286A5 (https=)
Ries et al. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to-A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy
Gilewski et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
Moingeon Cancer vaccines
Plotkin Vaccines: past, present and future
Jäger et al. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease
IL165003A0 (en) Ghrelin-carrier conjugates
NO20015073D0 (no) Vaksiner
JP2006506441A5 (https=)
Jin et al. Recent advances in carbohydrate-based cancer vaccines
JP2020504133A5 (https=)
US20170080064A1 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
JP2006514920A5 (https=)
CY1114041T1 (el) Ενεσιμα εμβολια εναντι πολλαπλων οροομαδων μηνιγγιτιδοκοκκου
JP2009515831A5 (https=)
JP2002531521A5 (https=)
Menon et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients
IL161146A0 (en) Antigen arrays for treatment of bone disease
JP2022549292A5 (https=)
JP2021518129A5 (https=)
JP2003530088A5 (https=)
Rong et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine
ES2322212T3 (es) Composicion de antigeno y linea celular que lleva el receptor manosa.
JP2021512966A5 (https=)
WO2001035989A3 (de) Verwendung von anti-idiotypische antikörpern als impfstoffe gegenkrebs